Publications by authors named "Andrew D Luber"

Claim this Profile
A
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses.
Mohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, Arezki Chekaoui, Dakota Newman, Andrew D Luber

JCI Insight· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health.
Hildegund C J Ertl, Sue L Currie, Andrew D Luber

Front Immunol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
David V Condoluci, Maryanne Andrews, Andrew D Luber

AIDS Read· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Peter J Ruane, Andrew D Luber, Mary Beth Wire, Yu Lou, Mark J Shelton

Antimicrob Agents Chemother· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.
Andrew D Luber

AIDS Read· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment strategies for highly treatment-experienced HIV-infected patients.
Andrew D Luber

Expert Rev Anti Infect Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic barriers to resistance and impact on clinical response.
Andrew D Luber

J Int AIDS Soc· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic barriers to resistance and impact on clinical response.
Andrew D Luber

MedGenMed· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
Peter J Ruane, Andrew D Luber

MedGenMed· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfuvirtide.
Jacob P Lalezari, Andrew D Luber

Drugs Today (Barc)· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis